



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Applicant(s): Jerussi et al.**Serial No. :** 10/663,173**Filed:** 09/16/2003**Confirmation No. :** 2834**Group Art Unit:** 1621**Examiner:** Davis, Brian J.

Title: TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE AND ITS FORMAMIDE

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is being:

- submitted together with the application being filed herein; or
- submitted for the first time; or
- submitted as a Supplemental Information Disclosure Statement in addition to an Information Disclosure Statement, which was filed on March 24, 2004; or filed together with the application on _____, and such submission is being made:
- under 37 CFR 1.97(b), within three months of filing national application or date of entry of international application, or before mailing date of first office action on the merits, whichever occurs last; or
- under 37 CFR 1.97(c) together with either a:
- Statement under 37 CFR 1.97(e); or
- \$180.00 fee under 37 CFR 1.17(p), after the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first; or
- under 37 CFR 1.97(d), filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee, together with a:
- Statement under 37 CFR 1.97(e); and
- \$180.00 fee under 37 CFR 1.17(p);
- and, furthermore, please note that this Information Disclosure Statement is being submitted:
- to disclose references cited in the Search Report in a related foreign application; and
- within 30 days of receipt of the Search Report (see 37 CFR 1.704(d)).
- Comment(s):

Applicant(s) submit herewith an Information Disclosure Citation form listing patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application, and for which there may be a duty to disclose in accordance with 37 CFR 1.56, together with any required copies of the listed references.

It is requested that the information disclosed herein be made of record in this application.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date of Deposit: May 18, 2005

Edward Timmer

Respectfully submitted,

Edward Timmer, Esq.
Attorney for Applicant(s)
Registration No. 46,248
Dated: May 18, 2005

HESLIN ROTHENBERG FARLEY & MESITI P.C.
5 Columbia Circle
Albany, New York 12203
Telephone: (518) 452-5600
Facsimile: (518) 452-5579

05/23/2005 NNGUYEN1 00000003 10663173

180.00 UP
02 FC:1806

**SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION**
(USE SEVERAL SHEETS IF NECESSARY)

ATTY DOCKET NO.
0701.196A

SERIAL NO.
10/663,173

APPLICANT(S)
JERUSSI ET AL.

FILING DATE
9/16/2003

GROUP
1621

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AF	5,788,986	08/04/98	Dodman			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							NO	YES	ABSTRACT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial here if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.